Given these findings, we aimed to determine the prevalence of PALB2 mutations in a Spanish population of BRCA1/BRCA2-negative breast/ovarian cancer families with either a personal or family history of pancreatic carcinoma. This evidence concerns the gene BRCA2 and ovarian carcinoma.